fatih.demirel

I overstated the effect on phenotype assignments, since correcting predicted risks leaves assignments unchanged when no one crosses the cutoff.

For classification, miscalibration changes how many people are assigned the wrong phenotype. For monitoring, it changes how many receive unnecessary ambulatory measurement or miss needed measurement, so validation should report those counts at the intended deployment prevalence.

Here the pathway claim should mean within-person temporal mediation; failure of podocyte changes to precede and statistically account for later fibrotic and cardiac changes would count against it.